The informed road map to prevention of Alzheimer Disease: A call to arms

Comorbid neuropathological diagnoses in early versus late-onset Alzheimer’s disease

(2021) Salvatore Spina et al.   BRAIN

Preclinical validation of a potent γ-secretase modulator for Alzheimer’s disease prevention

(2021) Kevin D. Rynearson et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Visualization of neurofibrillary tangle maturity in Alzheimer's disease: A clinicopathologic perspective for biomarker research

(2021) Christina M. Moloney et al.   Alzheimers & Dementia

Highly specific and ultrasensitive plasma test detects Abeta(1–42) and Abeta(1–40) in Alzheimer’s disease

(2021) Elisabeth H. Thijssen et al.   Scientific Reports

A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease

(2021) Stephen Salloway et al.   NATURE MEDICINE

Therapeutic approaches targeting Apolipoprotein E function in Alzheimer’s disease

(2020) Tosha Williams et al.   Molecular Neurodegeneration

Another step forward in blood-based diagnostics for Alzheimer’s disease

(2020) Randall J. Bateman et al.   NATURE MEDICINE

Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia

(2020) Shorena Janelidze et al.   NATURE MEDICINE

Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration

(2020) Elisabeth H. Thijssen et al.   NATURE MEDICINE

Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study

(2020) Eric M. Reiman et al.   Nature Communications

Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts

(2020) Thomas K Karikari et al.   LANCET NEUROLOGY

A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer’s disease

(2020) Nicolas R. Barthélemy et al.   NATURE MEDICINE

Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease

(2020) Shorena Janelidze et al.   Nature Communications

Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer’s disease and PET amyloid-positive patient identification

(2020) Nicolas R. Barthélemy et al.   Alzheimers Research & Therapy

Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer’s disease

(2020) Niklas Mattsson-Carlgren et al.   Science Advances

World‐Wide FINGERS Network: A global approach to risk reduction and prevention of dementia

(2020) Miia Kivipelto et al.   Alzheimers & Dementia

Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders

(2020) Sebastian Palmqvist et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Dementia prevention, intervention, and care: 2020 report of the Lancet Commission

(2020) Gill Livingston et al.   LANCET

Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease

(2020) Tiantian Guo et al.   Molecular Neurodegeneration

Tau molecular diversity contributes to clinical heterogeneity in Alzheimer’s disease

(2020) Simon Dujardin et al.   NATURE MEDICINE

Impact of TREM2R47H variant on tau pathology–induced gliosis and neurodegeneration

(2020) Maud Gratuze et al.   JOURNAL OF CLINICAL INVESTIGATION

U.S. POINTER (USA)

(2020) Laura D. Baker et al.   Alzheimers & Dementia

Comparison of ELISA- and SIMOA-based quantification of plasma Aβ ratios for early detection of cerebral amyloidosis

(2020) Steffi De Meyer et al.   Alzheimers Research & Therapy

Treatment Combinations for Alzheimer’s Disease: Current And Future Pharmacotherapy Options

(2019) Jeffrey L. Cummings et al.   JOURNAL OF ALZHEIMERS DISEASE

ApoE4: an emerging therapeutic target for Alzheimer’s disease

(2019) Mirna Safieh et al.   BMC Medicine

Emerging cerebrospinal fluid biomarkers in autosomal dominant Alzheimer's disease

(2019) Suzanne E. Schindler et al.   Alzheimers & Dementia

Clinical and biological effects of long-term lithium treatment in older adults with amnestic mild cognitive impairment: randomised clinical trial

(2019) Orestes V. Forlenza et al.   BRITISH JOURNAL OF PSYCHIATRY

Preliminary Results of a Trial of Atabecestat in Preclinical Alzheimer’s Disease

(2019) David Henley et al.   NEW ENGLAND JOURNAL OF MEDICINE

Randomized Trial of Verubecestat for Prodromal Alzheimer’s Disease

(2019) Michael F. Egan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tau Phosphorylation Rates Measured by Mass Spectrometry Differ in the Intracellular Brain vs. Extracellular Cerebrospinal Fluid Compartments and Are Differentially Affected by Alzheimer’s Disease

(2019) Nicolas R. Barthélemy et al.   Frontiers in Aging Neuroscience

α-synuclein in the pathophysiology of Alzheimer’s disease

(2019) Daniel Twohig et al.   Molecular Neurodegeneration

TREM2 function impedes tau seeding in neuritic plaques

(2019) Cheryl E. G. Leyns et al.   NATURE NEUROSCIENCE

High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis

(2019) Suzanne E. Schindler et al.   NEUROLOGY

Late-stage Anle138b treatment ameliorates tau pathology and metabolic decline in a mouse model of human Alzheimer’s disease tau

(2019) Matthias Brendel et al.   Alzheimers Research & Therapy

Resistance to autosomal dominant Alzheimer’s disease in an APOE3 Christchurch homozygote: a case report

(2019) Joseph F. Arboleda-Velasquez et al.   NATURE MEDICINE

Reactions to Multiple Ascending Doses of the Microtubule Stabilizer TPI-287 in Patients With Alzheimer Disease, Progressive Supranuclear Palsy, and Corticobasal Syndrome

(2019) Richard M. Tsai et al.   JAMA Neurology

NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease

(2018) Clifford R. Jack et al.   Alzheimers & Dementia

An Overview on the Clinical Development of Tau-Based Therapeutics

(2018) Miguel Medina   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

The Neurotoxic Role of Extracellular Tau Protein

(2018) Álvaro Sebastián-Serrano et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer’s Disease

(2018) Michael F. Egan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease

(2018) Lawrence S. Honig et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, tolerability and immunogenicity of an active anti-Aβ40 vaccine (ABvac40) in patients with Alzheimer’s disease: a randomised, double-blind, placebo-controlled, phase I trial

(2018) Ana-María Lacosta et al.   Alzheimers Research & Therapy

BACE inhibitors in clinical development for the treatment of Alzheimer’s disease

(2018) Francesco Panza et al.   Expert Review of Neurotherapeutics

New insights into the role of TREM2 in Alzheimer’s disease

(2018) Maud Gratuze et al.   Molecular Neurodegeneration

A tau homeostasis signature is linked with the cellular and regional vulnerability of excitatory neurons to tau pathology

(2018) Hongjun Fu et al.   NATURE NEUROSCIENCE

Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer’s disease: results of a randomized, double-blind, placebo-controlled phase 2a study

(2018) Philip Scheltens et al.   Alzheimers Research & Therapy

ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy

(2017) Yang Shi et al.   NATURE

Cryo-EM structures of tau filaments from Alzheimer’s disease

(2017) Anthony W. P. Fitzpatrick et al.   NATURE

Neocortical and hippocampal TREM2 protein levels during the progression of Alzheimer's disease

(2017) Sylvia E. Perez et al.   NEUROBIOLOGY OF AGING

Antisense Oligonucleotides: Translation from Mouse Models to Human Neurodegenerative Diseases

(2017) Kathleen M. Schoch et al.   NEURON

Elucidating the Role of TREM2 in Alzheimer’s Disease

(2017) Jason D. Ulrich et al.   NEURON

TREM2 deficiency attenuates neuroinflammation and protects against neurodegeneration in a mouse model of tauopathy

(2017) Cheryl E. G. Leyns et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy

(2017) Sarah L. DeVos et al.   Science Translational Medicine

TREM2, Microglia, and Neurodegenerative Diseases

(2017) Felix L. Yeh et al.   TRENDS IN MOLECULAR MEDICINE

The Effects of NOS2 Gene Deletion on Mice Expressing Mutated Human AβPP

(2017) Carol A. Colton et al.   JOURNAL OF ALZHEIMERS DISEASE

2016 Alzheimer's disease facts and figures

(2016)   Alzheimers & Dementia

Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer’s disease

(2016) Rik Ossenkoppele et al.   BRAIN

Apolipoprotein E as a Therapeutic Target in Alzheimer’s Disease: A Review of Basic Research and Clinical Evidence

(2016) Yu Yamazaki et al.   CNS DRUGS

The amyloid hypothesis of Alzheimer's disease at 25 years

(2016) Dennis J Selkoe et al.   EMBO Molecular Medicine

Two Phase 2 Multiple Ascending–Dose Studies of Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Mild-to-Moderate Alzheimer’s Disease

(2016) Florence Pasquier et al.   JOURNAL OF ALZHEIMERS DISEASE

TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques

(2016) Yaming Wang et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Overcoming translational barriers impeding development of Alzheimer's disease modifying therapies

(2016) Todd E. Golde   JOURNAL OF NEUROCHEMISTRY

The amyloid cascade hypothesis: are we poised for success or failure?

(2016) Eric Karran et al.   JOURNAL OF NEUROCHEMISTRY

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

(2016) Jeff Sevigny et al.   NATURE

Site-specific phosphorylation of tau inhibits amyloid-β toxicity in Alzheimer’s mice

(2016) Arne Ittner et al.   SCIENCE

BACE1 Physiological Functions May Limit Its Use as Therapeutic Target for Alzheimer's Disease

(2016) Soraia Barão et al.   TRENDS IN NEUROSCIENCES

Drug development in Alzheimer’s disease: the path to 2025

(2016) Jeffrey Cummings et al.   Alzheimers Research & Therapy

Reducing tau aggregates with anle138b delays disease progression in a mouse model of tauopathies

(2015) Jens Wagner et al.   ACTA NEUROPATHOLOGICA

Age and amyloid effects on human central nervous system amyloid-beta kinetics

(2015) Bruce W. Patterson et al.   ANNALS OF NEUROLOGY

Age-related macular degeneration: genome-wide association studies to translation

(2015) James R. M. Black et al.   GENETICS IN MEDICINE

The Platform Trial

(2015) Scott M. Berry et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Accelerated pericyte degeneration and blood–brain barrier breakdown in apolipoprotein E4 carriers with Alzheimer’s disease

(2015) Matthew R Halliday et al.   JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM

A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial

(2015) Tiia Ngandu et al.   LANCET

Genetics ignite focus on microglial inflammation in Alzheimer’s disease

(2015) Manasi Malik et al.   Molecular Neurodegeneration

Monitoring of chronic γ-secretase modulator treatment by serial amyloid-PET

(2015) M Brendel et al.   MOLECULAR PSYCHIATRY

Tau in physiology and pathology

(2015) Yipeng Wang et al.   NATURE REVIEWS NEUROSCIENCE

Peripheral and central effects of γ-secretase inhibition by semagacestat in Alzheimer’s disease

(2015) Rachelle S Doody et al.   Alzheimers Research & Therapy

Long-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer’s disease

(2015) Martin R Farlow et al.   Alzheimers Research & Therapy

Tau aggregation and its interplay with amyloid-β

(2014) Rebecca M. Nisbet et al.   ACTA NEUROPATHOLOGICA

APOE ε4 and the risk for Alzheimer disease and cognitive decline in African Americans and Yoruba

(2014) Hugh C. Hendrie et al.   INTERNATIONAL PSYCHOGERIATRICS

Harmonized diagnostic criteria for Alzheimer's disease: recommendations

(2014) J. C. Morris et al.   JOURNAL OF INTERNAL MEDICINE

Temporal gene profiling of the 5XFAD transgenic mouse model highlights the importance of microglial activation in Alzheimer’s disease

(2014) Véréna Landel et al.   Molecular Neurodegeneration

Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease

(2014) Stephen Salloway et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease

(2014) Rachelle S. Doody et al.   NEW ENGLAND JOURNAL OF MEDICINE

Apolipoprotein E, amyloid-beta, and neuroinflammation in Alzheimer’s disease

(2014) Evan Dorey et al.   Neuroscience Bulletin

Alzheimer’s disease drug-development pipeline: few candidates, frequent failures

(2014) Jeffrey L Cummings et al.   Alzheimers Research & Therapy

A Short Antisense Oligonucleotide Ameliorates Symptoms of Severe Mouse Models of Spinal Muscular Atrophy

(2014) Jeffrey M Keil et al.   Molecular Therapy-Nucleic Acids

Results of a follow-up study to the randomized Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT)

(2013)   Alzheimers & Dementia

Aminothienopyridazines and Methylene Blue Affect Tau Fibrillization via Cysteine Oxidation

(2013) Alex Crowe et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

APOE-ε2 and APOE-ε4 Correlate With Increased Amyloid Accumulation in Cerebral Vasculature

(2013) Peter T. Nelson et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study

(2013) Stephanie JB Vos et al.   LANCET NEUROLOGY

Tau pathology and neurodegeneration

(2013) Maria Grazia Spillantini et al.   LANCET NEUROLOGY

APOE genotype and MRI markers of cerebrovascular disease: Systematic review and meta-analysis

(2013) S. Schilling et al.   NEUROLOGY

A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease

(2013) Rachelle S. Doody et al.   NEW ENGLAND JOURNAL OF MEDICINE

Changes in Amyloid-  and Tau in the Cerebrospinal Fluid of Transgenic Mice Overexpressing Amyloid Precursor Protein

(2013) L. F. Maia et al.   Science Translational Medicine

Increased in Vivo Amyloid- 42 Production, Exchange, and Loss in Presenilin Mutation Carriers

(2013) R. Potter et al.   Science Translational Medicine

Safety and biomarker effects of solanezumab in patients with Alzheimer’s disease

(2012) Martin Farlow et al.   Alzheimers & Dementia

National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease

(2012) Bradley T. Hyman et al.   Alzheimers & Dementia

Mouse models of frontotemporal dementia

(2012) Erik D. Roberson   ANNALS OF NEUROLOGY

Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature

(2012) Peter T. Nelson et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

The Microtubule-Stabilizing Agent, Epothilone D, Reduces Axonal Dysfunction, Neurotoxicity, Cognitive Deficits, and Alzheimer-Like Pathology in an Interventional Study with Aged Tau Transgenic Mice

(2012) B. Zhang et al.   JOURNAL OF NEUROSCIENCE

Apolipoprotein E, Especially Apolipoprotein E4, Increases the Oligomerization of Amyloid   Peptide

(2012) T. Hashimoto et al.   JOURNAL OF NEUROSCIENCE

Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease

(2012) Randall J. Bateman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Memantine and cholinesterase inhibitor combination therapy for Alzheimer's disease: a systematic review

(2012) Lucy E Farrimond et al.   BMJ Open

The role of inflammatory processes in Alzheimer’s disease

(2012) G. Joseph Broussard et al.   INFLAMMOPHARMACOLOGY

Extended results of the Alzheimer’s disease anti-inflammatory prevention trial

(2011) John C. Breitner et al.   Alzheimers & Dementia

Stages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years

(2011) Heiko Braak et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

The projected effect of risk factor reduction on Alzheimer's disease prevalence

(2011) Deborah E Barnes et al.   LANCET NEUROLOGY

The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics

(2011) Eric Karran et al.   NATURE REVIEWS DRUG DISCOVERY

Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease

(2011) Randall J Bateman et al.   Alzheimers Research & Therapy

Accumulation of intraneuronal Aβ correlates with ApoE4 genotype

(2010) Ditte Z. Christensen et al.   ACTA NEUROPATHOLOGICA

Alzheimer's Disease Anti-Inflammatory Prevention Trial: Design, methods, and baseline results

(2009)   Alzheimers & Dementia

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade

(2009) Clifford R Jack et al.   LANCET NEUROLOGY

The amyloid cascade hypothesis

(2008) Amos D. Korczyn   Alzheimers & Dementia

A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics

(2008) Hanna Rosenmann et al.   EXPERIMENTAL NEUROLOGY

No Effect of One-Year Treatment with Indomethacin on Alzheimer's Disease Progression: A Randomized Controlled Trial

(2008) Daniëlle de Jong et al.   PLoS One

APOE genotype-specific differences in the innate immune response

(2007) Michael P. Vitek et al.   NEUROBIOLOGY OF AGING